Research Project on Reminders and Self-Sampling Can Increase Participation in Gynecology Cell Sampling - Preventive Examination Against Cervical Cancer.
Launched by KAROLINSKA INSTITUTET · Aug 18, 2019
Trial Information
Current as of June 26, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is studying how different ways of reminding women to get screened for cervical cancer can increase participation in these important screenings. Cervical cancer screening has been very successful in preventing cancer, but many women still do not attend. The researchers want to see if sending reminders via SMS (text messages) or electronic letters is more effective than traditional paper letters. They aim to find out if these modern methods can help more women get screened, which could lead to earlier detection and treatment of precancerous conditions, ultimately reducing the number of cervical cancer cases.
To be eligible for this trial, women living in the Region Skåne who meet certain criteria can participate. This includes women over 65 who haven't been screened in the last 10 years, those who have had abnormal cell changes that haven’t been followed up, or women who haven't been screened for more than 15 years. Participants can expect to receive different types of reminders about screening and will help researchers understand which method works best. Overall, the goal is to improve cervical cancer screening rates and ensure that more women can benefit from early detection and treatment.
Gender
FEMALE
Eligibility criteria
- Inclusion Criteria:
- • Women resident in Region Skane who either: 1) have had glandular cell transformation that has not been followed-up, 2) are older than 65 years and have had cell transformation that has not been followed-up or who have not participated in screening during the last 10 years, 3) women who have not been screened for more than 15 years.
- Exclusion Criteria:
- • No exclusion except those who do not consent.
About Karolinska Institutet
Karolinska Institutet is a renowned medical university located in Sweden, recognized for its commitment to advancing healthcare through innovative research and education. As a leading sponsor of clinical trials, the institution focuses on translating scientific discoveries into effective treatments and therapies, emphasizing patient-centered approaches. With a strong emphasis on collaboration and interdisciplinary research, Karolinska Institutet plays a pivotal role in addressing global health challenges and improving patient outcomes, leveraging its extensive network of experts and state-of-the-art facilities to drive clinical advancements.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Lund, Skåne, Sweden
Umeå, Västerbotten, Sweden
Gothenburg, Västra Götaland, Sweden
Stockholm, , Sweden
Uppsala, , Sweden
Linköping, östergötland, Sweden
Luleå, Norrbotten, Sweden
Jönköping, , Sweden
Lund, , Sweden
Gothenburg, , Sweden
Patients applied
Trial Officials
Miriam Elfström, PhD
Principal Investigator
Karolinska Institutet
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials